BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hangzhou Sumgen Biotech Co.\, Ltd. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Hangzhou Sumgen Biotech Co.\, Ltd
 .'s drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07764627-3173@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Sanritatug: Phase 2 readout est. (NCT07764627)
DESCRIPTION:Sanritatug\, phase 2.\nStudy: Study of SG301 for Renal AMR Afte
 r Transplantation\nEstimated primary completion: 31 March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/sanritatug#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07764627
URL:https://assetmemo.bio/drug/sanritatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06508983-3173@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Sanritatug: Phase 3 readout est. (NCT06508983)
DESCRIPTION:Sanritatug\, phase 3\, Multiple Myeloma.\nStudy: A Clinical Stu
 dy Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pom
 alidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Pat
 ients\nEstimated primary completion: 31 March 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/sanritatug#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06508983
URL:https://assetmemo.bio/drug/sanritatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06136988-2291@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Enlonstobart: Phase 1/2 readout est. (NCT06136988)
DESCRIPTION:Enlonstobart\, phase 1/2.\nStudy: A Study of Docetaxel for Inje
 ction (Albumin-bound) and SG001 in Combination With Cisplatin and Simultan
 eous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Ca
 rcinoma.\nEstimated primary completion: April 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/enlonstobart#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06136988
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07710248-3173@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20270517
DTEND;VALUE=DATE:20270518
SUMMARY:Sanritatug: Phase 2 readout est. (NCT07710248)
DESCRIPTION:Sanritatug\, phase 2.\nStudy: SG301-SC Injection Safety Study i
 n Subjects With Primary ITP Patients\nEstimated primary completion: 17 May
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/sanritatug#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0771024
 8
URL:https://assetmemo.bio/drug/sanritatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07454187-3217@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:SG2918: Phase 1/2 readout est. (NCT07454187)
DESCRIPTION:SG2918\, phase 1/2\, Multiple Myeloma.\nStudy: To Evaluate the 
 Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma\nEs
 timated primary completion: 30 September 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/sg2918#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07454187
URL:https://assetmemo.bio/drug/sg2918#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07447986-3173@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Sanritatug: Phase 2 readout est. (NCT07447986)
DESCRIPTION:Sanritatug\, phase 2\, Systemic Lupus Erythematosus.\nStudy: To
  Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus 
 Erythematosus\nEstimated primary completion: 30 September 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/sanritatug#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07447986
URL:https://assetmemo.bio/drug/sanritatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07282509-2291@assetmemo.bio
DTSTAMP:20261121T005030Z
DTSTART;VALUE=DATE:20280626
DTEND;VALUE=DATE:20280627
SUMMARY:Enlonstobart: Phase 1/2 readout est. (NCT07282509)
DESCRIPTION:Enlonstobart\, phase 1/2.\nStudy: Safety and Efficacy of Paclit
 axel Liposome Arterial Infusion Combined With Systemic Therapy for Second-
 Line Treatment of Advanced Liver Cancer\nEstimated primary completion: 26 
 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enlonstoba
 rt#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7282509
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
